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Abstract
The tetracycline (tet)-regulated expression system allows for the inducible overexpression of protein-coding genes, or
inducible gene knockdown based on expression of short hairpin RNAs (shRNAs). The system is widely used in mice, however
it requires robust expression of a tet transactivator protein (tTA or rtTA) in the cell type of interest. Here we used an in vivo
tet-regulated fluorescent reporter approach to characterise inducible gene/shRNA expression across a range of
hematopoietic cell types of several commonly used transgenic tet transactivator mouse strains. We find that even in
strains where the tet transactivator is expressed from a nominally ubiquitous promoter, the efficiency of tet-regulated
expression can be highly variable between hematopoietic lineages and between differentiation stages within a lineage. In
some cases tet-regulated reporter expression differs markedly between cells within a discrete, immunophenotypically
defined population, suggesting mosaic transactivator expression. A recently developed CAG-rtTA3 transgenic mouse
displays intense and efficient reporter expression in most blood cell types, establishing this strain as a highly effective tool
for probing hematopoietic development and disease. These findings have important implications for interpreting tet-
regulated hematopoietic phenotypes in mice, and identify mouse strains that provide optimal tet-regulated expression in
particular hematopoietic progenitor cell types and mature blood lineages.
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Introduction
Genetically modified mice are important tools for the study of
mammalian gene function in vivo. Targeted gene modification
using homologous recombination in mouse embryonic stem cells
allows production of mice with mutations in specific genes, and the
Cre/lox system allows conditional deletion of genes in particular
cell types [1–3]. The tetracycline (tet)-regulated expression system
is also widely used in mouse models, with the key advantage of
temporal and reversible control of transgene expression. Originally
developed for inducible gene overexpression [4–6], it also allows
inducible gene knockdown via expression of microRNA-based
short hairpin RNAs (shRNAs) [7–9].
The tet-regulated system requires two genetic components: a tet
response element (TRE) promoter controlling mRNA or shRNA
expression, and a recombinant tet-transactivator that can activate
the TRE promoter. The tTA (tet-off) transactivator binds and
activates the TRE promoter but is inhibited by the administration
of tetracycline or its commonly used analog doxycycline (Dox).
Conversely, the rtTA (tet-on) transactivator is latent until activated
by Dox. Therefore Dox indirectly controls expression from the
TRE by reversibly regulating transactivator function.
In vivo tet-regulated protein or shRNA expression is commonly
achieved by crossing mice carrying a TRE promoter cassette
transgene with mice carrying a tet transactivator transgene,
resulting in progeny carrying both genetic components. An
important factor in effective tet-regulated expression is the
genomic location of the TRE promoter cassette, which influences
its accessibility by the tet transactivator. Hence, recent approaches
have targeted the TRE cassette to defined genomic loci to optimise
inducible expression in most cell types [9,10]. A second key
determinant of effective tet-regulation is the expression level of the
tet transactivator. Many mouse strains have been generated that
express the tTA or rtTA transactivators under the control of
different promoters (www.tetsystems.com). Although many of
these promoters are nominally ubiquitous or tissue-specific, in
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most cases the pattern and abundance of transactivator expression
in these mouse strains is poorly characterised. In order to
optimally utilise transgenic, tet-regulated expression systems in
mice, and to rationally interpret the resulting phenotypes, an
understanding of the strength and breadth of transactivator
function in particular cell types in vivo is imperative. In this study
we have examined in vivo transactivator function across the
hematopoietic system of several commonly used transactivator
mouse strains.
Results
Characterising Tet-regulated Expression in
Hematopoietic Stem and Progenitor Cells
To examine tet-regulated expression in the hematopoietic
system of transgenic transactivator mouse strains, we utilised
a reporter mouse strain where expression of green fluorescent
protein (GFP) is under the control of the TRE promoter. The 39
UTR of the GFP-encoding transcript in this reporter strain also
includes a microRNA-based shRNA targeting firefly luciferase
(Luc.1309 or shLuc) [9]. We have previously used this TRE-GFP-
shLuc strain as a negative control in tet-regulated shRNA studies
[9,11]. The TRE-GFP-shLuc transgene is targeted to the collagen
type I alpha (Col1a1) locus, previously shown to facilitate tet-
regulated expression in a wide range of cell types in vivo [9,10].
GFP expression was negligible in hematopoietic cells of TRE-
GFP-shLuc single transgenic mice, verifying that reporter expres-
sion is not leaky (Figure S1).
We crossed reporter mice to various transgenic transactivator
mouse strains procured or produced by our laboratories. More
recently developed tet-on mouse strains often express the M2-rtTA
or rtTA3 transactivators, which have improved transcriptional
activity and Dox-sensitivity relative to the original rtTA protein
[12,13]. Of the six transgenic transactivator mouse strains we
examined, four express the tet-on transactivator: CAG-rtTA3 [9],
CMV-rtTA [14], ROSA26-M2rtTA [15], and Vav-rtTA3. The
CAG, CMV, and ROSA26 promoters are often regarded as
‘ubiquitous’ promoters and are widely used to drive a broad
expression pattern in transgenic mice. The CAG promoter
contains an enhancer element from human cytomegalovirus
(CMV) together with sequences from the chicken ß-actin promoter
and rabbit ß-globin genes that yield high level expression in
mammalian cells [16]. Similarly, the CMV promoter is based on
the strong promoter of the immediate early gene of human CMV
[17]. The ROSA26 promoter was originally identified based on its
broad expression pattern during mouse embryogenesis but is also
widely active in adult tissues [18,19]. In ROSA26-M2rtTA mice
M2rtTA expression is driven by the endogenous ROSA26
promoter, whereas the other five strains tested were all originally
generated by pronuclear injection of synthetic expression cassettes
resulting in variable transgene insertion site and copy number. To
complement the broadly acting tet-on mouse strains CAG-rtTA3,
CMV-rtTA, and ROSA26-M2rtTA, we used standard pronuclear
transgenesis to generate a transgenic mouse strain where
expression of the rtTA3 transactivator is under control of the
Vav promoter. Vav promoter activity is mainly restricted to the
hematopoietic compartment of mice, where it drives expression
across all blood cell types [20]. After screening several independent
transgenic founder lines we identified one (hereafter referred to as
Vav-rtTA3) that showed particularly effective tet-regulated re-
porter expression in blood cells (see below).
In addition to four tet-on mouse strains, we tested two
previously described transgenic strains that express the tet-off
transactivator from the well characterised hematopoietic promo-
ters Vav and Em. In contrast to the four tet-on strains, which were
all maintained on a C57BL/6 background, the two tet-off strains
were FVB/N strain background. Vav-tTA mice were originally
developed to drive tet-regulated oncogene expression across the
hematopoietic system [21]. Em-tTA mice express tTA under the
control of the immunoglobulin heavy chain (IgM) enhancer and
the SRa promoter [22]. The Em enhancer is particularly active in
developing B and T lymphocytes [23], and effectively drives
lymphoid-specific expression in mouse models [24].
In all cases adult mice carrying transactivator and reporter
transgenes developed normally and were analysed alongside
littermate single transgenic or wild type controls. For tet-on
strains, administering Dox food for one week prior to analysis
activated reporter expression. GFP expression was determined in
various hematopoietic cell types using flow cytometry of cells
isolated from bone marrow, spleen, thymus and blood. We initially
focused on stem cells and early progenitors of the lymphoid and
myeloid lineages. Using well-defined surface antigens to identify
cell types (Figure S2), we examined tet-regulated GFP reporter
expression in populations of cells enriched for hematopoietic stem
cells (HSCs), common myeloid progenitors (CMPs), granulocyte/
macrophage progenitors (GMPs), megakaryocyte/erythroid pro-
genitors (MEPs) and megakaryocyte progenitors (MkPs) (Figure 1).
Notably, each transactivator strain showed a distinct GFP
expression profile across these cell types. Of all the transactivator
strains analysed, CAG-rtTA3 consistently drove highly efficient
(near 100%) and intense GFP expression in HSCs and early
progenitors, with the exception of MEPs (Figure 1). GFP
expression driven by CMV-rtTA was similar to CAG-rtTA3 but
less uniformly intense, and approximately 10% of most progenitor
cell populations in this strain failed to express GFP. The ROSA26-
M2rtTA strain showed more heterogeneous GFP induction
between and within different stem and progenitor populations,
with poor expression intensity in HSCs compared with the CAG-
rtTA3 and CMV-rtTA strains. However ROSA26-M2rtTA drove
uniformly high reporter expression in MEPs, a cell type with weak
or heterogeneous reporter expression in the other five strains
examined (Figure 1). In keeping with the previously described pan-
hematopoietic expression pattern of the Vav promoter [20], we
observed reporter expression in all stem and progenitor cell types
of Dox-treated Vav-rtTA3 bitransgenic mice and untreated Vav-
tTA bitransgenic reporter mice (Figure 1). However both Vav
promoter-driven strains showed a significant proportion of GFP–
cells in each progenitor population, suggesting they are less
efficient than CAG-rtTA3 and CMV-rtTA for inducible expres-
sion in these cell types. Intriguingly, Em-tTA transactivator mice
drove appreciable GFP expression in HSCs and most progenitor
populations despite predicted lymphoid-specific activity (Figure 1).
Variable Transactivator Function in Differentiated
Hematopoietic Cell Types
We also examined tet-regulated GFP expression patterns in
more differentiated hematopoietic cell populations in the bone
marrow, spleen, thymus, and blood. Once again CAG-rtTA3 was
the most potent of the three ‘ubiquitous’ tet-on strains across more
mature cell types, with 85–100% GFP expression in thymocytes,
splenic B cells, bone marrow myeloid cells and blood platelets
(Figure 2). Reporter expression in immature CD4+CD8+ (DP)
thymocytes was efficient and intense in all strains apart from
CMV-rtTA, suggesting that this cell type is particularly amenable
to transactivator expression from different promoters. Strong
reporter expression in Em-tTA DP thymocytes is consistent with
a previous report where use of this strain to drive expression of
TRE-Myc resulted predominantly in DP T cell lymphoma [22].
Tet-Regulated Expression in Mouse Hematopoiesis
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Notably, all strains showed a dramatic reduction in the efficiency
of reporter expression in more mature, splenic CD8+ T
lymphocytes (Figure 2; see below). Reporter expression in splenic
B cells was also surprisingly poor in several strains, and only CAG-
rtTA3 drove intense reporter expression in a high proportion of
this cell population. We found that rtTA3 mRNA expression
correlated with GFP expression in splenic B cells of CAG-rtTA3;
TRE-GFP-shLuc mice (Figure S3), suggesting that transactivator
expression level is an important determinant of reporter expres-
sion. Interestingly, GFP expression in splenic B cells of untreated
Vav-tTA bitransgenic mice far outweighed that of their Dox-
treated Vav-rtTA3 counterparts, potentially due to different Vav
promoter activity based on transgene insertion site, transgene copy
number, or strain background. CAG-rtTA3 drove intense and
efficient GFP expression in bone marrow Gr1+Mac1+ myeloid
cells (predominantly neutrophils), a cell population that showed
Figure 1. Tet-regulated GFP reporter expression in hematopoietic stem cells and early progenitors of tet-transactivator transgenic
mice. Flow cytometry profiles of GFP expression in hematopoietic stem and progenitor cells isolated from the bone marrow of various transgenic
mouse strains. Profiles from a representative mouse (n = 2 mice analysed per genotype) carrying the indicated transactivator transgene along with
the TRE-GFP-shLuc reporter transgene are shown in green, with wild type controls shown in black. Tet-on bitransgenic reporter mice (CAG-rtTA3,
CMV-rtTA, ROSA26-M2rtTA, Vav-rtTA3) were given Dox food for 7 days before analysis, whereas tet-off bitransgenic reporter mice (Em-tTA and Vav-
tTA) were untreated. The percentage of GFP+ cells in each population is indicated. HSC: Lin–Sca1+Kit+ (LSK) hematopoietic stem cell. CLP: Lin–
KitIntSca1+CD127+ common lymphoid progenitor. CMP: Lin–Sca1–Kit+CD34+FccRII/III– common myeloid progenitor. GMP: Lin–Sca1–Kit+CD34+Fc-
cRII/III+ granulocyte/macrophage progenitor. MEP: Lin–Sca1–Kit+CD34–FccRII/III– megakaryocyte/erythroid progenitor. MkP: Lin–Sca1–
Kit+CD41+CD150+ megakaryocyte progenitor. Gating strategies are shown in Figure S2.
doi:10.1371/journal.pone.0054009.g001
Tet-Regulated Expression in Mouse Hematopoiesis
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very poor induction in most other strains (Figure 2). The highly
efficient reporter expression driven by CAG-rtTA3 in most cell
types indicates that the Col1a1-targeted reporter transgene is
amenable to transactivation across the hematopoietic system, and
further implicates transactivator expression level as a critical
determinant of reporter expression in different transactivator
strains (see Discussion).
Inducible Reporter Expression in Megakaryocytes/
platelets Correlates with Phenotype
Of all cell types examined, platelets showed the greatest
variability in reporter expression between different transactivator
strains. Platelets from CAG-rtTA3 and CMV-rtTA bitransgenic
reporter mice uniformly expressed high GFP levels, whereas in
other strains they were remarkably refractory to tet-regulated
expression (Figure 2). Reporter expression in platelets was
generally consistent with that in megakaryocyte precursors
(Figure 1). To verify that GFP reporter expression accurately
reflects transactivator function in platelets, we examined the
phenotypic effects of tet-regulated knockdown of an endogenous
gene in several transgenic transactivator strains. Bcl-xL (Bcl2l1) is
required for maintaining platelet survival in adult mice [25], and
we have previously shown that tet-regulated Bcl-xL knockdown in
megakaryocytes causes severe thrombocytopenia [11]. We crossed
TRE-GFP-shBcl-xL transgenic mice [11] to several transactivator
mice. Dox treatment of CAG-rtTA3; TRE-GFP-shBcl-xL mice
and CMV-rtTA; TRE-GFP-shBcl-xL mice induced severe throm-
bocytopenia, with platelet levels falling to less than 10% of those in
littermate controls or untreated mice (Figure 3). In contrast, Dox-
treated ROSA26-M2rtTA; TRE-GFP-shBcl-xL mice and un-
treated Vav-tTA; TRE-GFP-shBcl-xL mice maintained normal
platelet levels (Figure 3). These observations confirmed a close
correlation between reporter expression and functional tet-
regulated gene knockdown, and highlight marked differences in
the ability of several ‘ubiquitous’ transactivator mouse strains to
induce expression and associated phenotypes in a defined cell type.
Variable Tet-regulated Expression During T cell
Differentiation in vivo
Having noted that reporter expression in several transactivator
strains was far more efficient in developing, immature T cells in
the thymus relative to mature T cell populations in the spleen
(Figure 2), we tracked reporter expression during incremental
stages of T cell development in these organs (Figure 4, Figures S4
and S5). The CAG-rtTA3 strain drove efficient and intense
reporter expression throughout T cell development in the thymus,
transitioning from CD4–CD8– progenitors through to more
mature CD4+CD8– and CD4–CD8+ single positive (SP) popula-
tions (Figure 4A). In contrast, naı̈ve SP T lymphocytes in the
spleen of these mice only showed weak reporter expression
(Figure 4B). This may be explained by poor CAG promoter
activity and low rtTA3 expression in naı̈ve T cells, however given
that all transactivator strains displayed poor reporter expression in
this cell type (Figure S4) we cannot rule out inaccessibility of the
TRE-GFP-shLuc reporter transgene. Remarkably, high level GFP
expression was restored in a large proportion of effector and
memory T cells (Figure 4B). As most splenic T cells are naı̈ve, the
reporter expression observed in splenic T cell subsets is consistent
with a preponderance of GFP-low cells in the total splenic T cell
population (Figure 2).
In vivo Kinetics of Tet-on and Tet-off Reporter Expression
A major strength of tet-regulated systems is rapid induction or
repression of a protein-coding gene or shRNA. Having demon-
strated particularly effective tet-regulated expression in DP
thymocytes of Vav promoter-driven tet-on (Vav-rtTA3; TRE-
GFP-shLuc) and tet-off (Vav-tTA; TRE-GFP-shLuc) mice
(Figure 2), we investigated the in vivo kinetics of GFP induction
and repression respectively in this cell population upon doxycy-
cline treatment. Time course analysis revealed rapid reporter
induction in Vav-rtTA3; TRE-GFP-shLuc mice, with over 30% of
DP thymocytes expressing GFP after one day of Dox treatment
(Figure 5A). Notably, after only 2 days of treatment approximately
60% of DP thymocytes were GFP+, most of which comprised
a distinct GFP-high peak. The proportion of thymocytes
expressing GFP reached near-maximum levels (.90%) after four
days on Dox (Figure 5A). A similarly high proportion of
thymocytes from the corresponding untreated Vav-tTA; TRE-
GFP-shLuc tet-off reporter mice expressed high GFP levels, which
gradually diminished upon Dox treatment (Figure 5B). Approx-
imately 70% of thymocytes remained GFP+ after 4 days of Dox
treatment in vivo, albeit with low fluorescence intensity. In
principle the half-life of a tet-regulated overexpressed protein (in
this case GFP) dictates its rate of decay upon de-induction, and
likely contributes to the slower rate of reporter repression relative
to induction we observed in thymocytes (Figure 5A and 5B).
Natural Variation in Tet-regulated Expression
Throughout our analyses we observed appreciable variability in
the proportion of GFP+ cells and the pattern of GFP fluorescence
intensity between bitransgenic reporter mice matched for sex, age,
and genotype. Although in most cases this was minor (Figure 5C),
it demonstrates significant variability of transactivator expression
or function between individual mice. This variation may be based
on stochastic epigenetic effects at the transactivator or tet-
responsive transgenes, and may also be influenced by differences
in the developmental and immunological history of individual
mice.
Discussion
Inducible gene over-expression or knockdown in mice using the
tet-regulated expression system has proven very useful for
understanding gene function in vivo. Although a multitude of tet
transactivator transgenic mice have been developed, in many cases
the pattern and level of transactivator expression and resulting
TRE-driven protein or shRNA expression are poorly charac-
terised. In this study we have used flow cytometry to systematically
measure the tet-regulated expression of a fluorescent protein
reporter across the hematopoietic system of several different tet
transactivator mouse strains. This provided a unique opportunity
to accurately quantitate not only the proportion of a particular cell
type with reporter expression, but also expression level per cell
based on fluorescence intensity.
A key finding of this study was the degree of heterogeneity in
reporter expression in several mouse strains where transactivator
expression is under the control of a nominally ubiquitous promoter
such as CMV or ROSA26. This heterogeneity occurred at three
levels. Firstly, reporter expression often varied markedly between
different cell lineages within a transactivator mouse. For example
CMV-rtTA reporter mice showed highly efficient GFP induction
in the megakaryocyte/platelet lineage, however expression in
myeloid and lymphoid cells was poor compared with other strains.
Secondly, we observed differences in reporter expression between
developmental stages within particular hematopoietic lineages.
Tet-Regulated Expression in Mouse Hematopoiesis
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This was especially evident in the T cell lineage, where in all
strains examined there was a dramatic fall in reporter expression
in peripheral, naive T cell subsets compared with their immature
progenitors in the thymus. In several strains we also noted
decreased reporter expression in platelets compared with their
megakaryocyte progenitors. These findings clearly caution against
extrapolating reporter expression from one differentiation stage to
another, and suggest that as progenitor cells proliferate and
Figure 2. Tet-regulated GFP reporter expression in developing and mature hematopoietic cells of tet-transactivator transgenic
mice. Flow cytometry profiles are as described in Figure 1. Thymocytes: CD4+CD8+ thymocytes. T cells: CD3+ splenocytes. B cells: B220+ splenocytes.
Myeloid cells: Gr1+Mac1+ bone marrow cells. Platelets: CD41+ peripheral blood (plasma) cells. Profiles are from a representative mouse (n = 2–6
analysed per genotype).
doi:10.1371/journal.pone.0054009.g002
Tet-Regulated Expression in Mouse Hematopoiesis
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differentiate down a particular lineage the expression of tet-
regulated transgenes can fluctuate significantly. This is an inherent
drawback of regulated transcription systems, and contrasts with
the ‘hit-and-run’ genetic changes induced using Cre/lox based
mouse models. A third and particularly problematic feature of
some transactivator mouse strains examined was significant
variability in reporter expression between cells within an
immunophenotypically defined cell population. In principle this
variation can be explained by mosaic transactivator expression
and/or accessibility of the TRE response transgene at the Col1a1
locus. This locus was originally chosen as a transgenic ‘landing
pad’ because it supports transgene expression even in cell types
that do not normally express Col1a1 [10]. However we note that
Col1a1 is expressed at low but uniform levels across the wide
range of mouse hematopoietic cell types analysed in the
‘‘Immunological Genome Project’’ (www.immgen.org) [26]. In-
deed our results revealed a remarkable, near-100% induction of
TRE-reporter expression in most cell types of the CAG-rtTA3
strain, confirming that the Col1a1 locus is highly amenable to
reporter transactivation across the hematopoietic system. This is
consistent with our previous observations in other tissues [27]. An
exception is naı̈ve, splenic T cells, in which we noted poor reporter
expression in all transactivator strains. This raises the possibility of
silencing of the Col1a1-targeted tet responsive transgene in this cell
type, perhaps associated with the high degree of chromatin
condensation in naı̈ve T cells relative to activated/memory T cells
[28]. Previous retroviral and transgenic studies have also noted low
level expression of CMV-based promoters in the T cell lineage
[29–31].
Our results suggest that sub-optimal transactivator protein
expression limits reporter induction in the ‘ubiquitous’ transacti-
vator strains CMV-rtTA and ROSA26-M2rtTA. The activity of
transgenic promoters lacking normal regulatory elements can be
subject to position effects associated with epigenetic silencing [32].
However ROSA26-M2rtTA is a knockin transgene that makes use
of the endogenous ROSA26 promoter, therefore the basis of
variable transactivator expression within certain cell types of this
strain remains unclear.
Of the six transgenic strains tested, CAG-rtTA3 was the most
effective driver of reporter expression across multiple hematopoi-
etic cell types. This was exemplified by high efficiency reporter
expression in bone marrow myeloid cells and platelets, cell types
refractory to tet-regulated expression in most if not all other
strains. Efficient expression across almost all hematopoietic cell
types is consistent with our previous observations in non-
hematopoietic tissues [9], and establishes the CAG-rtTA3 strain
as a highly effective driver of tet-regulated expression across the
great majority of cell types examined. However we noted poor
CAG-rtTA3-driven reporter expression in MEPs and a significant
proportion of splenic B cells, emphasising the need for validation
of transactivator function in cell types of interest even within
broadly effective transactivator strains.
It is often desirable to restrict tet-regulated expression to the
hematopoietic compartment. For example, previous models of
oncogene addiction or tumour suppressor hypersensitivity in
leukemia and lymphoma have relied on transgenic mice where
transactivator expression is controlled by the largely hematopoi-
etic-specific Em or Vav promoters [8,21,22]. Although our results
Figure 3. Transactivator-specific thrombocytopenia associated with Bcl-xL knockdown in megakaryocytes/platelets. Peripheral blood
platelet counts of ROSA26-M2rtTA; TRE-GFP-shBcl-xL, CMV-rtTA; TRE-GFP-shBcl-xL, CAG-rtTA3; TRE-GFP-shBcl-xL, and Vav-tTA; TRE-GFP-shBcl-xL. Mice
were either untreated (tet-off mice) or doxycycline treated for one week (tet-on mice) prior to blood sampling. Mice were bled between 6 and 14
weeks of age.
doi:10.1371/journal.pone.0054009.g003
Tet-Regulated Expression in Mouse Hematopoiesis
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suggest that Vav-tTA, Vav-rtTA3, and Em-tTA transgenic mice
display robust tet-regulated reporter expression in many hemato-
poietic cell types, expression in stem, progenitor, and myeloid cells
of these strains was clearly sub-optimal relative to the highly
effective CAG-rtTA3 strain. In principle, efficient yet hematopoi-
etic-specific tet-regulation can be achieved by transplanting bone
marrow or fetal liver-derived hematopoietic stem cells derived
from CAG-rtTA3 or other effective ‘ubiquitous’ promoter-driven
transactivator mice into lethally irradiated wild type mice. The
resulting chimeric reconstituted mice should allow robust Dox-
dependent expression across the hematopoietic system with
minimal effects on non-hematopoietic tissues.
While highlighting the potential heterogeneity of tet-regulated
expression across the hematopoietic system in vivo, our study also
emphasises the power of fluorescent reporter flow cytometry for
analysis and isolation of cells with optimal tet-regulated inducible
expression from a mixed population. For tet-regulated over-
expression of a gene of interest, reporter co-expression can be
achieved using bicistronic expression cassettes based on internal
ribosome entry sites (IRES) or 2A peptides [33]. Similarly, tet-
regulated gene knockdown can be tracked by including shRNA
sequences in the 39 UTR of the reporter transcript. The TRE-
GFP-shRNA configuration used in this study has been optimised
for both GFP expression and target gene knockdown [9].
Figure 4. GFP reporter expression in T cell subsets of CAG-rtTA3 mice. Flow cytometry profile of GFP expression in thymic and splenic T cell
subsets from a representative CAG-rtTA3 bitransgenic reporter mouse (green) compared with a control mouse (black). Mice were given Dox food for
7 days before analysis. The percentage of GFP+ cells in each population is indicated. (A) Reporter expression during thymocyte differentiation
through DN (CD4–CD8–) to DP (CD4+CD8+) to SP (CD4+CD8– and CD4–CD8+) stages. (B) Reporter expression in splenic T cell subsets. Naı̈ve:
CD62L+CD44–, Effector: CD62L–CD44+, Effector memory: CD44+CD127+CD62L–, Central memory: CD44+CD127+CD62L+. Gating strategies are
shown in Figure S5.
doi:10.1371/journal.pone.0054009.g004
Tet-Regulated Expression in Mouse Hematopoiesis
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In summary, we have systematically characterised tet-regulated
expression across the hematopoietic system of several transacti-
vator mouse strains. The reporter expression patterns described
here allow an informed choice of the most appropriate
transactivator transgenic strain for investigation of a certain
hematopoietic cell type or process, and provide a basis for the
accurate interpretation of hematopoietic phenotypes generated
using these strains. Furthermore we have found that CAG-rtTA3
transgenic mice facilitate intense and efficient inducible gene
regulation across the majority of blood cell types, establishing this




All animal experiments were approved by the Walter and Eliza
Hall Institute Animal Ethics Committee.
Transgenic Mice
Mouse strains described previously include TRE-GFP-shLuc
and CAG-rtTA3 [9], TRE-GFP-shBclxL [11], CMV-rtTA [14],
ROSA26-M2rtTA [15], Vav-tTA [21], and Em-tTA [22]. The
Vav-rtTA3 mouse strain was made by cloning rtTA3 coding
sequences into the Vav promoter vector HS21/45 [20], which was
used for standard pronuclear transgenesis. Several transgenic
founder lines were screened in vivo by crossing to the TRE-GFP-
shLuc transgenic reporter, and the Vav-rtTA3 strain was chosen
based on optimal reporter expression in blood cells. The four tet-
on transgenic lines were maintained on a C57BL/6 strain
background, and the two tet-off transgenic lines on a FVB/N
background. To minimise strain background effects, we analysed
F1 progeny derived from mating TRE-GFP-shRNA transgenics
with transactivator transgenics. The rtTA transgene was detected
using forward (GCTTGGTGTAGAGCAGCCTACAC) and re-
verse (CAGCGCTGAGTGCATATAACGCG) primers, yielding
a 311 bp product. The M2rtTA transgene was detected using
forward (ACGGCGCTCTGGAATTACTCAATGG) and reverse
(AGAAGCCTTGCTGACACAGGAACGC) primers, yielding
a 345 bp product. The rtTA3 transgenes were detected using
forward (CTGCTGTCCATTCCTTATTC) and reverse
(CGAAACTCTGGTTGACATG) primers, yielding a 303 bp




TRE-GFP-shRNA transgenes were genotyped as described
[11]. The rtTA, M2rtTA, rtTA3, and tTA transgene genotyping
protocols are provided in Figures S1, S2, S3, S4, S5. Doxycycline
was administered in the diet at 600 mg/kg food (Specialty Feeds,
Glen Forrest, Western Australia).
Flow Cytometry and Blood Analysis
Blood was collected from the retro-orbital plexus and platelet
cell counts were measured with an Advia 2120 hematological
analyser (Bayer, Leverkusen, Germany). To stain mature hema-
topoietic cells, single cell suspensions were prepared from bone
marrow, thymus, spleen and peripheral blood. Following red
blood cell lysis, cells were stained with APC-conjugated anti-B220
(BD553092), anti-CD8 (BD553035), or anti-Gr1 (BD553129), or
PE-conjugated anti-CD3 (BD555275), anti-CD4 (BD553049) or
anti-Mac1 (BD557397). Cell preparations were also stained with
propidium iodide (Sigma-Aldrich, St Louis, MO) and only live
cells were displayed. Platelet-rich plasma was prepared by
centrifuging blood in phosphate buffered saline at 1256g for 7
minutes, and stained with PE-conjugated anti-CD41 antibody
BD558040 (BD Biosciences, San Jose, CA). Stained cells were
analysed by flow cytometry (FACSCalibur, BD Biosciences, San
Jose, CA). FACS data were analyzed with FlowJo software (Tree
Star, Ashland, OR). For staining of CMP, GMP and MEP
populations, single cell suspensions from bone marrow were
incubated with a collection of biotinylated mature linage markers
(anti-CD4, CD8, B220, Ter119, Gr1, Mac1 antibodies) followed
by staining with PE-Texas Red-conjugated Streptavidin antibody
(BD551487) along with PECy7-conjugated anti-Sca1 (BD558162),
PCPCy5.5-conjugated Kit (BD560557), AF647-conjugated CD34
(BD5602330), and PE-conjugated FcgRII/III (BD553145). For
staining of MkP, single cell suspensions from bone marrow were
incubated with a collection of biotinylated mature linage markers,
PECy7-conjugated Sca1, PCPCy5.5-conjugated Kit, PE-conju-
gated CD41 (BD558040) and APC-conjugated CD150 (Biolegend
115910) followed by staining with PE-Texas Red-conjugated
Streptavidin antibody. For staining of CLP, single cell suspensions
from bone marrow were stained with a collection of PE-
Figure 5. Kinetics and variability of GFP reporter expression. (A, B) Flow cytometry profiles of GFP expression in CD4+CD8+ thymocytes from
representative Vav-rtTA3; TRE-GFP-shLuc (A) and Vav-tTA; TRE-GFP-shLuc (B) mice during a time course of Dox treatment. (C) Flow cytometry of GFP
expression in peripheral blood B220+ B cells of four different Vav-tTA; TRE-GFP-shLuc mice. The percentage of GFP+ cells ranged from 92–97% as
indicated.
doi:10.1371/journal.pone.0054009.g005
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conjugated mature linage markers, PECy7-conjugated Sca1,
PCPCy5.5-conjugated Kit and biotinylated CD127 (BD555288)
followed by staining with APC-conjugated Streptavidin antibody
(BD554067). Cell preparations were also stained with Fluoro-
GoldTM (Sigma-Aldrich, St Louis, MO) and only live cells were
displayed. Stained cells were analysed by flow cytometry (LSR II,
BD Biosciences, San Jose, CA). Gating strategies are shown in
Figure S2. For staining of different subsets of T cells in spleen,
single cell suspension from spleen was stained with APC-
conjugated CD4 (BD561830), Pacific Blue-conjugated CD8
(BD558106), PE-Cy7-conjugated CD62L (BD560516), PE-conju-
gated CD44 (BD561860) and APC-conjugated CD127
(eBioscience 17-1271-82). Samples were analysed on FACSCanto
(BD Biosciences, San Jose, CA). Gating strategies are shown in
Figure S5.
Expression Analysis
RNA was extracted from sorted cells using an RNeasy kit
(QIAGEN, Valencia, CA). rtTA3 expression was determined by
RT-qPCR (Platinum SYBR Green; Invitrogen, Carlsbad, CA)
using forward primer TTACACTGGGCTGCGTATTG and
reverse primer AGAAGTGGGGGCATAGAATC.
Supporting Information
Figure S1 GFP reporter expression in TRE-GFP-shLuc
single transgenic mice. Flow cytometry profiles of GFP
expression in thymocytes (CD4+CD8+ thymocytes), T cells
(CD3+ splenocytes), B cells (B220+ splenocytes), and myeloid cells
(Gr1+Mac1+ bone marrow cells) from representative TRE-GFP-
shLuc single transgenic reporter mice (untreated shown in red, 7
day Dox treated shown in green). Wild type control is shown in
black.
(TIF)
Figure S2 Gating strategy for hematopoietic stem cells
and early progenitors. Adapted from [34].
(TIF)
Figure S3 Transactivator expression in GFP– and GFP+
cell populations. RT-qPCR analysis of rtTA3 expression in
GFP– and GFP+ B cells (B220+) sorted from the spleen of
a representative CAG-rtTA3; TRE-GFP-shLuc mouse, compared
with non-transgenic control.
(TIF)
Figure S4 GFP reporter expression in T cell subsets of
CMV-rtTA and ROSA26-M2rtTA mice. Flow cytometry
profiles of GFP expression in thymic and splenic T cell subsets
from representative CMV-rtTA or ROSA26-M2rtTA bitrans-
genic reporter mice (green) compared with a control mice (black).
Mice were given Dox food for 7 days before analysis. The
percentage of GFP+ cells in each population is indicated. (A)
Reporter expression during thymocyte differentiation through DN
(CD4–CD8–) to DP (CD4+CD8+) to SP (CD4+CD8– and CD4–
CD8+) stages. (B) Reporter expression in splenic T cell subsets.
Naı̈ve: CD62L+CD44–, Effector: CD62L–CD44+, Effector mem-
ory: CD44+CD127+CD62L–, Central memory:
CD44+CD127+CD62L+. Gating strategies are shown in Figure
S5.
(TIF)
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